Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open, offering critical ...

Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...

New poll reveals Americans' mixed views on weight-loss drugs for obesity treatment, especially regarding teen use.

Gut bacteria-produced exopolysaccharides (EPS) help regulate metabolism by modulating gut microbiota, promoting SCFA ...

TNF Pharmaceuticals (TNFA), announced that it has initiated the first in a series of studies to evaluate the impact of its novel oral TNF-alpha ...

FuturHealth, a leading provider of personalized weight-loss solutions, today announced the appointment of Dr. Brian Solow to ...

20 in the Annals of Surgery. Seth Z. Aschen, M.D., from Weill Cornell Medicine in New York City, and colleagues examined the rates of surgical complications and postoperative readmission in patients ...

Not only is alcohol a risk to your liver, but it can also significantly increase your risk for multiple types of cancer, a ...

Ozempic, Mounjaro, and other glucagon-like peptide-1 medications, otherwise known as GLP-1s, are changing how Americans shop for groceries. In early January, Food & Wine published a story about ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down ... been published in the New England Journal of Medicine. Professors Wassilios Meissner and Olivier ...

尽管如此，目前针对GLP-1RAs的系统性评估仍然有限，其在多种健康结局上的具体效果尚未被全面解析。 为填补这一空白，1月20日Nature Medicine的研究 ...